Browse > Article
http://dx.doi.org/10.4333/KPS.2009.39.2.107

Physicochemical property and skin damage of physical mixture of valsartan and polysorbate 80  

Choi, Han-Gon (College of Pharmacy, Yeungnam University)
Sung, Jun-Ho (College of Pharmacy, Yeungnam University)
Oh, Dong-Hoon (College of Pharmacy, Yeungnam University)
Li, Dong-Xun (College of Pharmacy, Yeungnam University)
Cho, Kwan-Hyung (College of Pharmacy, Yeungnam University)
Woo, Jong-Soo (College of Pharmacy, Yeungnam University)
Yong, Chul-Soon (College of Pharmacy, Yeungnam University)
Publication Information
Journal of Pharmaceutical Investigation / v.39, no.2, 2009 , pp. 107-110 More about this Journal
Abstract
To investigate the interaction and skin damage of valsartan with polysorbate 80, the physical mixture of valsartan and polysorbate 80 was prepared and then its adhesion, dispersibility, DSC and skin damage in nude rats were investigated. The physical mixture of valsartan and polysorbate 80 appeared as an aggregated form and could hardly be dispersed in water. The DSC curve showed that physical mixture disappeared the intrinsic peaks of valsartan and polysorbate 80 at about $115^{\circ}C$ and $170^{\circ}C$, respectively. It appeared a new relatively broad endothermic peak at about $150^{\circ}C$, suggesting that valsartan was chemically interacted with polysorbate 80. Furthermore, it induced the severe skin irritation and damage in nude mice. Thus, polysorbate 80 must not be used in the preparation of valsartan-loaded pharmaceutical dosage forms.
Keywords
Valsartan; Polysorbate 80; Physical mixture; Skin damage;
Citations & Related Records
연도 인용수 순위
  • Reference
1 S. Oparil, S. Dyke, F. Harris, J. Kief, D. James, A. Hester and S. Fitzsimmons, The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension, Clin Ther., 18 (5), (1996).   DOI   ScienceOn
2 F. Waldmeier, G. Flesch, P. MuLler, T. Winkler, H.P. Kriemler, P. Buhlmayer and M.D. Gasparo, Pharmacokinetics, disposition and biotransformation of [14C]- radiolabelled valsartan in healthy male volunteers after a single oral dose, Xenobiotica, 27 (1), 59–71 (1997).
3 M.D. Gasparo and S. Whitebread, Binding of valsartan to mammalian angiotensin AT1 receptors, Regul. Pept., 59, 303-311 (1995).   DOI   ScienceOn
4 Y. Mizuta, H. Kai, M. Fukui and T. Imaizumi, Long-term treatment with valsartan attenuates myocardial fibrosis and improves diastolic dysfunction in hypertensive patients The echorcardiographic assessment, J. of Cardiac Failure, 14 (7), S150 (2008).   DOI   ScienceOn
5 L.M. Prisant, K.L. Thomas, E.F. Lewis, Z. Huang, G.S. Francis, W. D. Weaver, M.A. Pfeffer, J.J.V. McMurray, R.M. Califf and E.J. Velazquez, Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both, J. Am. Coll. Cardiol., 51 (19), 1865-1871 (2008).   DOI   ScienceOn
6 C.J. Mbah, Solubilization of valsartan by aqueous glycerol, polyethylene glycol and micellar solutions, Pharmazie., 61 (4), 322-324 (2006).
7 B. Cappello, C.D. Maio, M. Iervilino and A. Miro, Improvement of solubility and stability of valsartan by hydroxypropyl-$\beta$-cyclodextrin, J. Inclusion Phenom. Macrocyclic Chem., 54, 289-294 (2006).   DOI
8 P.D Martino, R. Censi, C. Barthélémy, R. Gobetto, E. Joiris, A. Masic, P. Odou and S. Martelli, Characterization and compaction behaviour of nimesulide crystal forms, Int. J. Pharm., 342 (1), 137-144 (2007).   DOI   ScienceOn
9 M. Schierholz, Physico-chemical properties of a rifampicinreleasing polydimethylsiloxane shunt, Biomaterials. 18 (8), 635-641 (1997).   DOI   ScienceOn
10 L. Benassi, G. Bertazzoni, C. Magnoni, M. Rinaldi, C. Fontanesi and S. Seidenari, Decrease in toxic potential of mixed tensides maintained below the critical micelle concentration: an in vitro study, Skin Pharmacol Appl Skin Physiol., 16 (3), 156-164 (2003).   DOI   ScienceOn
11 S. Zalac, M.Z. Khan, V. Gabelica, M. Tudja, E. Mestrovic and M. Romih, Paracetamol-propyphenazone interaction and formulation difficulties associated with eutectic formation in combination solid dosage forms, Chem. Pharm. Bull,, 47 (3), 302-307 (1999).   DOI   ScienceOn
12 G.L. Amidon, H. Lennernäs, V.P. Shah and J.R. Crison, A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm. Res., 12, 413-420 (1995).   DOI   ScienceOn
13 W. Wasylaschuk, P. Harmon, G. Wagner, A. Harman, A. Templeton, H. Xu and R. Reed, Evaluation of hydroperoxides in common pharmaceutical excipients, J. Pharm. Sci., 96 (1), 106-116 (2007).   DOI   ScienceOn
14 A.N. Hassan and J.F. Frank, Influence of surfactant hydrophobicity on the detachment of Escherichia coli O157:H7 from lettuce, Int. J. Food Microbiol., 87 (1-2), 145-152 (2003).   DOI   ScienceOn
15 C.F. Rawlinson, A.C. Williams, P. Timmins and I. Grimsey, Polymer-mediated disruption of drug crystallinity, Int. J. Pharm., 336 (1), 42-48 (2007).   DOI   ScienceOn
16 B.C. Hancock and G. Zografi, Characteristics and significance of the amorphous state in pharmaceutical systems, J. Pharm. Sci., 86 (1), 1–12 (1997).   DOI   ScienceOn
17 J.L. Pool, R. Glazer, M. Weinberger, R. Alvarado, J. Huang and A. Graff, Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: A double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults, Clin Ther., 29 (1), 61-73 (2007).   DOI   ScienceOn
18 S. Sheetal, K.B. Anil, K.S. Rakesh, B. Tanim, M. Amarnath and M. Amarnath, Pharmacoscintigraphic Evaluation of Polysorbate 80-Coated Chitosan Nanoparticles for Brain Targeting, American J. of Drug Delivery, 3(3), 205-212 (2005).   DOI   ScienceOn
19 L.A. Felton, T. Austin-Forbes and T.A. Moore, Influence of surfactants in aqueous-based polymeric dispersions on the thermomechanical and adhesive properties of acrylic films, Drug Dev. Ind. Pharm., 26 (2), 205-210 (2000).   DOI   ScienceOn